Spruce Biosciences, Inc.(SPRB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SPRB Spruce Biosciences, Inc.

Market Closed 02-06 16:00:00 EST

72.40

+1.55

+2.19%

盘后72.40

+0.000.00%

18:14 EST

High74.40	Low71.00	Vol30.00K
Open71.17	D1 Closing70.85	Amplitude4.80%
Mkt Cap77.16M	Tradable Cap63.52M	Total Shares1.07M
T/O2.17M	T/O Rate3.42%	Tradable Shares877.30K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SPRB","market":"US","secType":"STK","nameCN":"Spruce Biosciences, Inc.","latestPrice":72.4,"timestamp":1770411600000,"preClose":70.85,"halted":0,"volume":29999,"hourTrading":{"tag":"盘后","latestPrice":72.4,"preClose":72.4,"latestTime":"18:14 EST","volume":145,"amount":10588.62,"timestamp":1770419642400,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.021877205363444056,"floatShares":877301,"shares":1065700,"eps":-82.47875,"marketStatus":"Market Closed","change":1.55,"latestTime":"02-06 16:00:00 EST","open":71.17,"high":74.4,"low":71,"amount":2167290.65457,"amplitude":0.047989,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-82.47875,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"listingDate":1602216000000,"exchange":"NASDAQ","adjPreClose":70.85,"preHourTrading":{"tag":"盘前","latestPrice":71.5,"preClose":70.85,"latestTime":"09:29 EST","volume":201,"amount":14333.459745,"timestamp":1770388199127,"change":0.65,"changeRate":0.009174,"amplitude":0.04446},"postHourTrading":{"tag":"盘后","latestPrice":72.4,"preClose":72.4,"latestTime":"18:14 EST","volume":145,"amount":10588.62,"timestamp":1770419642400,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.2819756856984703,"impliedVol":0.883,"impliedVolPercentile":0.88},"requestUrl":"/m/hq/s/SPRB","defaultTab":"news","newsList":[{"id":"2609086581","title":"Spruce Biosciences Reports Long-Term Efficacy of Tralesinidase Alfa in Sanfilippo Syndrome Type B","url":"https://stock-news.laohu8.com/highlight/detail?id=2609086581","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609086581?lang=en_us&edition=fundamental","pubTime":"2026-02-06 05:07","pubTimestamp":1770325631,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire  on February 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL5TLk7q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRB"],"gpt_icon":0},{"id":"2608879683","title":"Spruce Biosciences Appoints Daven Mody and Bruno Gagnon to Executive Leadership Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2608879683","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608879683?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:02","pubTimestamp":1770123726,"startTime":"0","endTime":"0","summary":"Spruce Biosciences Inc. has announced the appointments of Daven Mody, Pharm.D., as Senior Vice President of Regulatory and Quality, and Bruno Gagnon, B.Pharm., M.Sc., as Senior Vice President, Clinical Development Operations. Mody brings extensive experience in regulatory filings and approvals, while Gagnon has more than 30 years of experience in leading clinical operations for global drug development programs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire  on February 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL3H5LgF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB","BK4139"],"gpt_icon":0},{"id":"2606719752","title":"Spruce Biosciences Reports Positive Long-Term Results for Tralesinidase Alfa in Sanfilippo Syndrome Type B","url":"https://stock-news.laohu8.com/highlight/detail?id=2606719752","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606719752?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:01","pubTimestamp":1769605262,"startTime":"0","endTime":"0","summary":"Spruce Biosciences Inc. has announced upcoming presentations of clinical data regarding its investigational enzyme replacement therapy, tralesinidase alfa , for the treatment of Sanfilippo syndrome type B . The data, to be presented at the 22nd Annual WORLDSymposium from February 2-6, 2026 in San Diego, will include findings on the long-term administration of TA-ERT, showing its impact on reducing heparan sulfate levels and stabilizing cognitive function and cortical gray matter volume in patients. Additionally, a separate presentation will detail divergent neurocognitive outcomes in two siblings with MPS IIIB, one treated with TA-ERT and the other receiving supportive care. The results have not yet been presented and are scheduled for February 5, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and sho","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDL773dGB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB","BK4139"],"gpt_icon":0},{"id":"2606001217","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2606001217","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606001217?lang=en_us&edition=fundamental","pubTime":"2026-01-26 20:27","pubTimestamp":1769430467,"startTime":"0","endTime":"0","summary":"Battalion Oil  shares were 380% higher pre-bell Monday after the company said late Friday that it has entered into a gas-treating agreement with a large-cap midstream company.Brand Engagement Network  stock was up 220%, extending Friday's rally.USA Rare Earth  shares were 22% higher after the company said it has secured potential access to $1.60 billion in government funding.Spruce Biosciences  stock was up 16%, rebounding from Friday's losses.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BATL","BK4168","BK4139","USAR","BK4134","SPRB","BNAI","BK4213"],"gpt_icon":1},{"id":"2605492104","title":"Big-Pharma Partner Harbour BioMed Boosts Stake In Spruce Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2605492104","media":"Benzinga","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605492104?lang=en_us&edition=fundamental","pubTime":"2026-01-21 20:24","pubTimestamp":1768998240,"startTime":"0","endTime":"0","summary":"Harbour BioMed exercises its warrant to buy Spruce Biosciences shares, raising its stake to about 3.8% as the companies work together on the SPR202 drug program.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/21/lab--Medical-Hospital-Research-Laborator.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/21/lab--Medical-Hospital-Research-Laborator.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/m-a/26/01/50031377/big-pharma-partner-harbour-biomed-boosts-stake-in-spruce-biosciences","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/m-a/26/01/50031377/big-pharma-partner-harbour-biomed-boosts-stake-in-spruce-biosciences","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["LU0882574055.USD","LU1323610961.USD","LU1868837300.USD","LU1670711040.USD","AZN","LU0237698245.USD","IE0002141913.USD","LU1670710661.SGD","LU0114720955.EUR","LU2456880835.USD","LU1718418525.SGD","LU1868836591.USD","LU0889565916.HKD","LU2360032135.SGD","LU1571399168.USD","LU1670710588.SGD","LU1868837136.USD","IE00BFTCPJ56.SGD","LU1032466523.USD","LU0225771236.USD","LU1585245621.USD","LU2125154778.USD","LU1868836914.USD","IE00BJJMRZ35.SGD","LU2236285917.USD","LU0061475181.USD","LU0306806265.USD","BK4568","LU2417539215.USD","LU1093756325.SGD","SPRB","LU1093756168.USD","BK4007","LU0320765992.SGD","LU1261432733.SGD","LU1829250122.USD","BK4581","BK4559","LU2242652126.USD","BK4588","LU1430594728.SGD","BK4532","IE00BFXG1179.USD","LU2462157665.USD","LU1868836757.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU1670711123.USD","BMY","LU2133065610.SGD"],"gpt_icon":0},{"id":"2604153636","title":"Harbour BioMet acquires common stock in Spruce Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2604153636","media":"TIPRANKS","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604153636?lang=en_us&edition=fundamental","pubTime":"2026-01-20 04:10","pubTimestamp":1768853414,"startTime":"0","endTime":"0","summary":"Harbour BioMed announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in Spruce Biosciences (...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/harbour-biomet-acquires-common-stock-in-spruce-biosciences-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/harbour-biomet-acquires-common-stock-in-spruce-biosciences-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SPRB"],"gpt_icon":0},{"id":"2604908969","title":"HBM Holdings Deepens Ties With Spruce Biosciences via Warrant Exercise","url":"https://stock-news.laohu8.com/highlight/detail?id=2604908969","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604908969?lang=en_us&edition=fundamental","pubTime":"2026-01-19 08:08","pubTimestamp":1768781322,"startTime":"0","endTime":"0","summary":"HBM Holdings Ltd. ( ($HK:2142) ) has shared an announcement. HBM Holdings Limited has exercised a warrant obtained under its license and collaborat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/hbm-holdings-deepens-ties-with-spruce-biosciences-via-warrant-exercise?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/hbm-holdings-deepens-ties-with-spruce-biosciences-via-warrant-exercise?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4168","SPRB","BK4139","HBM"],"gpt_icon":0},{"id":"2604497070","title":"HBM Holdings Acquires 3.8% Stake in Spruce Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2604497070","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604497070?lang=en_us&edition=fundamental","pubTime":"2026-01-19 08:01","pubTimestamp":1768780903,"startTime":"0","endTime":"0","summary":"HBM Holdings Ltd. has exercised a warrant under its license and collaboration agreement with Spruce Biosciences Inc., resulting in an equity investment in Spruce. Following the exercise of the warrant on January 19, 2026, HBM Holdings and its affiliate HBM Alpha Therapeutics now hold approximately 3.8% of Spruce’s total outstanding shares and about 3.1% of its fully diluted shares, based on figures as of September 30, 2025. The transaction does not trigger any reporting, announcement, or shareholders' approval requirements under Chapter 14 of the Hong Kong Listing Rules, as none of the applicable percentage ratios reach 5% or more.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to g","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nNDL6ykB5t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","SPRB","BK4139","02142","BK1161"],"gpt_icon":0},{"id":"2601362581","title":"BRIEF-Spruce Biosciences Secures Up To $50 Million In Growth Capital From Avenue Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2601362581","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601362581?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:23","pubTimestamp":1767878630,"startTime":"0","endTime":"0","summary":"BRIEF-Spruce Biosciences Secures Up To $50 Million In Growth Capital From Avenue CapitalJan 8 (Reuters) - Spruce Biosciences Inc SPRB.O:SPRUCE BIOSCIENCES SECURES UP TO $50 MILLION IN GROWTH CAPITAL F","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA80HMRL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB","BK4139"],"gpt_icon":0},{"id":"2601364521","title":"Spruce Biosciences Secures $50 Million Loan Facility from Avenue Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2601364521","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601364521?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:02","pubTimestamp":1767877335,"startTime":"0","endTime":"0","summary":"Spruce Biosciences, Inc., a late-stage biopharmaceutical company focused on therapies for neurological disorders, has entered into a new loan facility with Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital Group. The agreement provides Spruce with up to $50 million in growth capital, including an initial $15 million tranche to be funded around January 9, 2026. The remaining $35 million is available in additional tranches, subject to the achievement of key regulatory and commercial milestones related to the development and planned commercial launch of tralesinidase alfa enzyme replacement therapy  for Sanfilippo Syndrome Type B . The loan has a 42-month term and is aimed at supporting the company’s operations, regulatory filings, and pre-launch commercial activities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for inf","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL8MHH80:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB","BK4139"],"gpt_icon":0},{"id":"2601364375","title":"Spruce Biosciences Inc - Initial Funding of $15 Mln Extends Cash Runway Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2601364375","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601364375?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:00","pubTimestamp":1767877206,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA80HMRL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRB"],"gpt_icon":0},{"id":"2601036482","title":"Spruce Biosciences Secures up to $50 Million in Growth Capital From Avenue Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2601036482","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601036482?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:00","pubTimestamp":1767877206,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA80HMRL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRB"],"gpt_icon":0},{"id":"2593549007","title":"BUZZ-Oppenheimer starts Spruce Biosciences with \"outperform\" rating on rare disease strength","url":"https://stock-news.laohu8.com/highlight/detail?id=2593549007","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593549007?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:12","pubTimestamp":1766495535,"startTime":"0","endTime":"0","summary":"BUZZ-Oppenheimer starts Spruce Biosciences with \"outperform\" rating on rare disease strength** Oppenheimer initiates coverage on Spruce Biosciences SPRB.O with \"outperform\" rating and $283 PT** PT imp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nL6N3XT0KV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMRN","SPRB","IE00B7SZLL34.SGD","IE00B19Z3581.USD","BK4139","IE00B19Z3B42.SGD","IE0002270589.USD","BK4566"],"gpt_icon":0},{"id":"2593148468","title":"Spruce Biosciences Coverage Assumed by HC Wainwright & Co. at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2593148468","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593148468?lang=en_us&edition=fundamental","pubTime":"2025-12-22 19:41","pubTimestamp":1766403660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SPRB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 22, 2025 06:41 ET (11:41 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRB"],"gpt_icon":0},{"id":"2593481457","title":"Refile-Spruce Biosciences, Inc. : H.c. Wainwright Assumes Coverage With Buy Rating and Target Price $220 (Clarifies to Say Assumes Coverage)","url":"https://stock-news.laohu8.com/highlight/detail?id=2593481457","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593481457?lang=en_us&edition=fundamental","pubTime":"2025-12-22 19:21","pubTimestamp":1766402489,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nL4N3XS0M5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRB","BK4139"],"gpt_icon":0},{"id":"2593481359","title":"Spruce Biosciences, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating  and Target Price $220","url":"https://stock-news.laohu8.com/highlight/detail?id=2593481359","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593481359?lang=en_us&edition=fundamental","pubTime":"2025-12-22 19:09","pubTimestamp":1766401760,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nAZN4RI2ZN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRB"],"gpt_icon":0},{"id":"2591124649","title":"Spruce Biosciences Sets New Director Compensation Terms with Stock Options and Retainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2591124649","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591124649?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:06","pubTimestamp":1765803961,"startTime":"0","endTime":"0","summary":"Spruce Biosciences Inc. has appointed Keli Walbert to its board of directors, effective immediately. As part of the company's non-employee director compensation policy, Walbert has been granted a nonstatutory stock option to purchase 3,400 shares of common stock, vesting monthly over three years. She will receive an annual cash retainer of $40,000 for her role as director and $5,000 for serving on the Compensation Committee, both pro-rated for 2025. Starting January 1, 2026, the Compensation Committee retainer will increase to $5,500. From the 2026 Annual Meeting, Walbert will also be eligible for an annual stock option to purchase 1,700 shares, vesting by the next annual meeting or one year from grant, whichever comes first.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDLsmvlw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB","BK4139"],"gpt_icon":0},{"id":"2591649994","title":"Spruce Biosciences Appoints Keli Walbert to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2591649994","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591649994?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:01","pubTimestamp":1765803675,"startTime":"0","endTime":"0","summary":"Spruce Biosciences Inc. has appointed Keli Walbert to its Board of Directors. Walbert brings over 20 years of commercial leadership experience in the pharmaceutical industry, including her recent role as Executive Vice President, U.S. Commercial, at Horizon Therapeutics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire  on December 15, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL37BWxx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2112291526.USD","BK4139","SPRB","BK4534","LU0868494617.USD","LU1057294990.SGD","IE00BJJMRZ35.SGD","BK4599","IE00B4R5TH58.HKD","LU2089984988.USD","LU2242652126.USD","LU1061106388.HKD","LU0122379950.USD","IE00B2B36J28.USD","BK4588","AMGN","LU0058720904.USD","IE00BJT1NW94.SGD","LU1571399168.USD","LU2468319806.SGD","BK4533","LU0289739699.SGD","IE0002141913.USD","LU1023059063.AUD","IE00BFTCPJ56.SGD","BK4585","LU0889565916.HKD","IE0009355771.USD","LU2242646821.SGD","LU0320765992.SGD","LU1983299246.USD","SG9999001440.SGD","LU0109394709.USD","BK4581","BK4566"],"gpt_icon":0},{"id":"2591649661","title":"Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2591649661","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591649661?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:00","pubTimestamp":1765803606,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUAQKR4C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRB"],"gpt_icon":0},{"id":"2591689054","title":"Spruce Biosciences Reprices Stock Options to Boost Employee Retention","url":"https://stock-news.laohu8.com/highlight/detail?id=2591689054","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591689054?lang=en_us&edition=fundamental","pubTime":"2025-12-13 05:04","pubTimestamp":1765573468,"startTime":"0","endTime":"0","summary":"Spruce Biosciences Inc. has approved a stock option repricing plan, effective December 11, 2025. Under this plan, the exercise price of certain outstanding stock options held by employees and directors, including executive officers, has been reduced to the market price of the company's common stock as of the effective date. The repriced options will only become exercisable at the reduced price after a designated retention period, which lasts up to twelve months, until FDA approval of the company's tralesinidase alfa product candidate, or a change in control, whichever occurs first. The repriced options include 11,666 options for CEO Javier Szwarcberg and 6,131 options for CFO Samir Gharib.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL5hF7mk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sprucebiosciences.com","stockEarnings":[{"period":"1week","weight":-0.0664},{"period":"1month","weight":-0.0729},{"period":"3month","weight":-0.4299},{"period":"6month","weight":535.2963},{"period":"1year","weight":177.589},{"period":"ytd","weight":-0.1689}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0293},{"period":"6month","weight":0.0839},{"period":"1year","weight":0.139},{"period":"ytd","weight":0.0128}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.190445},{"month":2,"riseRate":0.5,"avgChangeRate":0.001406},{"month":3,"riseRate":0,"avgChangeRate":-0.288755},{"month":4,"riseRate":0,"avgChangeRate":-0.208561},{"month":5,"riseRate":0.4,"avgChangeRate":-0.03765},{"month":6,"riseRate":0.4,"avgChangeRate":-0.079875},{"month":7,"riseRate":0.6,"avgChangeRate":0.089441},{"month":8,"riseRate":0.4,"avgChangeRate":0.028537},{"month":9,"riseRate":0.4,"avgChangeRate":-0.136102},{"month":10,"riseRate":0.4,"avgChangeRate":2.105377},{"month":11,"riseRate":0.5,"avgChangeRate":0.001192},{"month":12,"riseRate":0.333333,"avgChangeRate":0.217863}],"exchange":"NASDAQ","name":"Spruce Biosciences, Inc.","nameEN":"Spruce Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Spruce Biosciences, Inc.(SPRB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Spruce Biosciences, Inc.(SPRB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Spruce Biosciences, Inc.,SPRB,Spruce Biosciences, Inc.股票,Spruce Biosciences, Inc.股票老虎,Spruce Biosciences, Inc.股票老虎国际,Spruce Biosciences, Inc.行情,Spruce Biosciences, Inc.股票行情,Spruce Biosciences, Inc.股价,Spruce Biosciences, Inc.股市,Spruce Biosciences, Inc.股票价格,Spruce Biosciences, Inc.股票交易,Spruce Biosciences, Inc.股票购买,Spruce Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Spruce Biosciences, Inc.(SPRB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Spruce Biosciences, Inc.(SPRB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction